$322 Million is the total value of Opaleye Management Inc.'s 45 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 30.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OCUL | OCULAR THERAPEUTIX INC | $29,575,000 | -29.0% | 5,974,800 | 0.0% | 9.18% | +4.0% | |
| CDXS | CODEXIS INC | $27,734,000 | -34.1% | 1,345,000 | 0.0% | 8.61% | -3.4% | |
| CMRX | Buy | CHIMERIX INC | $27,038,000 | -24.6% | 5,903,450 | +5.8% | 8.40% | +10.3% |
| HROW | Buy | HARROW HEALTH INC | $22,447,000 | -20.9% | 3,291,343 | +0.2% | 6.97% | +15.8% |
| CRNX | Sell | CRINETICS PHARMACEUTICALS INC | $15,211,000 | -26.1% | 693,000 | -4.3% | 4.72% | +8.2% |
| CYTK | Sell | CYTOKINETICS INC | $14,963,000 | -43.4% | 406,500 | -29.9% | 4.65% | -17.1% |
| KROS | KEROS THERAPEUTICS INC | $14,451,000 | -7.1% | 265,750 | 0.0% | 4.49% | +36.1% | |
| TARA | Buy | PROTARA THERAPEUTICS INC | $13,664,000 | -24.1% | 2,674,031 | +0.9% | 4.24% | +11.2% |
| RETA | Buy | REATA PHARMACEUTICALS INCclass a | $13,333,000 | +53.2% | 407,002 | +23.3% | 4.14% | +124.3% |
| KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $11,058,000 | -8.3% | 1,112,500 | +8.5% | 3.43% | +34.2% |
| ETON | Sell | ETON PHARMACEUTICALS INC | $10,374,000 | +1.4% | 2,379,275 | -0.2% | 3.22% | +48.5% |
| STXS | Sell | STEREOTAXIS INC | $8,936,000 | -43.0% | 2,395,600 | -5.2% | 2.78% | -16.5% |
| MRUS | Buy | MERUS N.V. | $8,937,000 | -11.6% | 338,000 | +6.4% | 2.78% | +29.5% |
| TCON | Buy | TRACON PHARMACEUTICALS INC | $8,298,000 | -1.9% | 3,155,098 | +3.3% | 2.58% | +43.6% |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $7,679,000 | – | 175,000 | +100.0% | 2.38% | – |
| XOMA | Sell | XOMA CORP DEL | $7,583,000 | +7.5% | 271,000 | -19.9% | 2.36% | +57.4% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $6,659,000 | -79.6% | 195,500 | -76.8% | 2.07% | -70.1% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $5,956,000 | -49.1% | 251,500 | -26.5% | 1.85% | -25.4% |
| TELA | Buy | TELA BIO INC | $5,548,000 | -3.6% | 477,000 | +6.0% | 1.72% | +41.1% |
| FBIO | FORTRESS BIOTECH INC | $5,100,000 | -45.6% | 3,750,000 | 0.0% | 1.58% | -20.3% | |
| PCVX | Sell | VAXCYTE INC | $5,096,000 | -32.2% | 211,000 | -33.2% | 1.58% | -0.6% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS INC | $4,914,000 | -2.2% | 325,000 | +41.9% | 1.53% | +43.2% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $3,822,000 | -59.9% | 943,702 | +6.8% | 1.19% | -41.3% |
| GINKGO BIOWORKS HOLDINGS INCclass a shares | $3,747,000 | -51.5% | 929,780 | 0.0% | 1.16% | -29.0% | ||
| SMLR | Sell | SEMLER SCIENTIFIC INC | $3,469,000 | -78.0% | 70,000 | -59.3% | 1.08% | -67.8% |
| MGNX | Sell | MACROGENICS INC | $3,316,000 | -55.3% | 376,400 | -18.5% | 1.03% | -34.5% |
| VSTM | VERASTEM INC | $3,278,000 | -31.2% | 2,325,000 | 0.0% | 1.02% | +0.7% | |
| FULC | New | FULCRUM THERAPEUTICS INC | $3,216,000 | – | 136,000 | +100.0% | 1.00% | – |
| MASS | New | 908 DEVICES INC | $3,163,000 | – | 166,406 | +100.0% | 0.98% | – |
| EWTX | New | EDGEWISE THERAPEUTICS INC | $2,939,000 | – | 303,000 | +100.0% | 0.91% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $2,833,000 | – | 710,000 | +100.0% | 0.88% | – |
| HYPERFINE INC | $2,701,000 | -51.1% | 763,075 | 0.0% | 0.84% | -28.4% | ||
| SYBX | Buy | SYNLOGIC INC | $2,362,000 | +14.8% | 984,200 | +15.8% | 0.73% | +68.3% |
| PRQR | Buy | PROQR THERAPEUTICS NV | $2,195,000 | -80.9% | 2,425,000 | +68.9% | 0.68% | -72.0% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $1,485,000 | -70.6% | 790,000 | -24.6% | 0.46% | -57.0% |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $1,342,000 | +8.7% | 240,000 | -8.9% | 0.42% | +59.2% |
| GRPH | New | GRAPHITE BIO INC | $1,303,000 | – | 255,500 | +100.0% | 0.40% | – |
| LQDA | Buy | LIQUIDIA CORPORATION | $1,284,000 | +1465.9% | 178,800 | +964.3% | 0.40% | +2247.1% |
| New | MODULAR MEDICAL INC | $1,171,000 | – | 266,100 | +100.0% | 0.36% | – | |
| Sell | AVALO THERAPEUTICS INC | $1,054,000 | -57.5% | 1,454,400 | -0.3% | 0.33% | -37.8% | |
| NCNA | Sell | NUCANA PLCsponsored adr | $878,000 | -69.0% | 878,700 | -26.1% | 0.27% | -54.5% |
| RPTX | New | REPARE THERAPEUTICS INC | $793,000 | – | 55,678 | +100.0% | 0.25% | – |
| STRO | Sell | SUTRO BIOPHARMA INC | $740,000 | -92.7% | 89,980 | -86.8% | 0.23% | -89.3% |
| New | JOURNEY MEDICINE CORP | $324,000 | – | 67,000 | +100.0% | 0.10% | – | |
| BLRX | BIOLINERX LTDsponsored ads | $29,000 | -14.7% | 16,667 | 0.0% | 0.01% | +28.6% | |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -1,315,000 | -100.0% | -0.74% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -165,778 | -100.0% | -0.76% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INC | $0 | – | -328,100 | -100.0% | -1.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.